We performed a pilot-study on pegylated liposomal doxorubicin (PLD) for advanced hepatocellular carcinoma. Seventeen patients received 40 mg/m(2) PLD intravenously every 4 weeks. A clinical benefit response was achieved in 50% (complete remission 7%, minor remission 7%, stable disease 36%). Toxicities were moderate. In view of these encouraging findings, further studies appear warranted.
No takes yet. Share an insight, caveat, or question.
Schmidinger et al. (2001) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: